Flurry of international orders for Chinese covid vaccines

 

• At least 10 countries have signed up for the shots from Sinopharm and other providers
• It’s an opportunity for Beijing to burnish its global reputation but it all depends on transparency, observers say
• Pakistan and Hungary were among the string of countries lining up to order coronavirus vaccines from China as Chinese regulators 

  approved the country’s first Covid-19 shot.

  The vaccine, developed under state-owned Sinopharm, was approved for conditional market use on Thursday after reporting 

  79 per cent efficacy

   against the disease in interim results, according to Chinese health officials who gave few details about how the assessment was made.

  The approval is a milestone for Beijing, which has played up its plans to make its vaccines a “global public good” and could make a big difference to the very limited supplies, according to analysts.

  At least 10 countries in Latin America, the Middle East and Asia have signed up for doses from China’s vaccine developers, which also include Sinovac Biotech and CanSino Biologics.

  A day earlier Ukraine signed a contract to buy 1.8 million doses from Sinovac. The company has yet to announce results of its global trials, but, like Sinopharm, was granted emergency use authorisation in China in July.

  Drew Thompson, a visiting senior research fellow at the Lee Kuan Yew School of Public Policy at the National University of Singapore, said supplying vaccines was “an important benchmark for China in terms of its status”.

  Dominic Meagher, a visiting fellow at the Australian National University, agreed that it would be a “win for China” and global public health if China could successfully roll out Chinese vaccines.

  But it was a highly complex task and it was not clear how it would play out, he said.

  “Until people are actually vaccinated safely and effectively, it’s a promise,” said Meagher, who is researching China’s response to Covid-19.

  Egypt is also among countries to already receive doses of the Sinopharm vaccine. Its health ministry signed a letter of intent for Covid-19 vaccine cooperation with China on Thursday, according to the Chinese embassy in Cairo.

  Along with Morocco, Egypt is expected to be a production centre for Covid-19 distribution in Africa.

  One of the Sinopharm vaccine’s advantages is that it can be stored and transported at normal fridge temperatures. If competitively priced, the vaccine could be a “game changer” in the sector, according to global health governance researcher Sara Davies.

  But officials have released very little information about the analysis of the vaccine, saying only that trials included 60,000 people in several countries, mild fever occurred in less than 0.1 per cent of the participants and there was a serious allergic reaction in about two per million.

  The vaccine has yet to be endorsed by the World Health Organization, a gold standard for domestic regulators and UN agencies placing vaccine orders.

  That might be the next hurdle for the Sinopharm vaccine, according to Davies.

  “It’s one thing to be able to get countries signing on. It’s another to say you are a leader – to do that there has to be transparency and that international seal of approval,” she said.

• Pakistan joined that list with an announcement on Thursday, saying it planned to buy 1.2 million doses from the company. The two-dose jabs, enough to cover 600,000 people, are the country’s first official confirmation of a vaccine purchase.
• Hungary also expressed interest in Covid-19 vaccines from China, with a senior official saying the country planned to rely on shots obtained directly from China or through a European Union procurement mechanism.
• Observers said that by supplying vaccines to the rest of the world, China had a chance to bolster its international reputation and partnerships.
• “It’s definitely a point of prestige for China to have vaccines, not just for its domestic needs, but to provide abroad, just like the major US pharmaceutical companies and Russia pharmaceutical companies,” Thompson said.
• Sinopharm’s vaccines are already 

  in use in the United Arab Emirates

   and Bahrain, countries that hosted clinical trials for the shots. Both countries gave emergency use authorisation for the doses, followed by approval earlier last month.
• “It’s got all the bells and whistles to be a big deal, but we just need more information. It’s really important if China wants to claim leadership [in global vaccine supply] and reach a bigger market, they are going to have to start coming forward with a lot more information,” said Davies, a professor at Griffith University in Australia.
• An executive from Sinopharm subsidiary China National Biotec Group, which is responsible for developing the vaccine, said more details would be released and published in scientific journals.
• On Thursday, the WHO gave its first emergency use validation for a Covid-19 vaccine to Pfizer-BioNTech.

• https://www.scmp.com/news/china/science/article/3116135/coronavirus-flurry-international-orders-chinese-vaccines